Overall market sentiment has been high on CytomX Therapeutics Inc (CTMX) stock lately. CTMX receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.
CytomX Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CTMX!
What is Stock Sentiment?
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.
InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.
The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.
What's Happening With CTMX Stock Today?
CytomX Therapeutics Inc (CTMX) stock is trading at $2.84 as of 10:22 AM on Friday, Jan 27, a rise of $0.06, or 2.16% from the previous closing price of $2.78. The stock has traded between $2.73 and $2.84 so far today. Volume today is low. So far 521,964 shares have traded compared to average volume of 4,038,720 shares.
To screen for more stocks like CytomX Therapeutics Inc click here.
More About CytomX Therapeutics Inc
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platform. The company probody technology platform to create proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. The company focuses on developing Probody therapeutics which addresses clinically-validated cancer targets in immuno-oncology that are difficult to drug and lead to concerns about damage to healthy tissues or toxicities.
Click Here to get the full Stock Report for CytomX Therapeutics Inc stock.